Mat2a inhibitor and/or tsg101 inhibitor for use in antiviral therapy
AssigneeCambridge Enterprise Limited
InventorsColin Michael CRUMP, Laura Grace CALLER
Life of this patent
Estimating the term…
Abstract
The invention relates to MAT2A inhibitors and/or TSG101 inhibitors for treating or preventing viral infection in a subject. More specifically, the invention relates to MAT2A inhibitors and/or TSG101 inhibitors for treating or preventing viral infections caused by DNA viruses or nuclear replicating viruses. The invention also relates to MAT2A inhibitors and/or TSG101 inhibitors for treating or preventing viral infections caused by RNA viruses.
Claims39
A MAT2A inhibitor and/or a TSG101 inhibitor for use in a method of treating or preventing a viral infection in a subject.
A method for treating or preventing a viral infection in a subject, the method comprising administering to the subject a MAT2A inhibitor and/or a TSG101 inhibitor.
Use of a MAT2A inhibitor and/or a TSG101 inhibitor in the treatment or prevention of a viral infection in a subject.
Dependencies are inferred from the claim text.